Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002123 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
A Phase 3 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002123: Completed Phase 3 study, sponsored by Pharmacia and Upjohn.
NCT00002123 is a Phase 3 study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002123, a Phase 3 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
Interventions
- DRUG Didanosine
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002123
The ClinicalTrials.gov registry entry for NCT00002123 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Didanosine is the first listed.
NCT00002123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002123 about?
NCT00002123 is a clinical study titled "A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3". To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
What is the current status of trial NCT00002123?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002123?
The interventions under investigation include: Didanosine (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002123?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.